Bank of America’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-25,300
| Closed | -$1.97M | – | 7669 |
|
|
2025
Q3 | $1.97M | Sell |
25,300
-21,500
| -46% | -$1.68M | ﹤0.01% | 4834 |
|
|
2025
Q2 | $3.66M | Buy |
46,800
+1,800
| +4% | +$134K | ﹤0.01% | 4203 |
|
|
2025
Q1 | $3.26M | Sell |
45,000
-81,300
| -64% | -$5.82M | ﹤0.01% | 4235 |
|
|
2024
Q4 | $9.35M | Buy |
+126,300
| New | +$8.84M | ﹤0.01% | 3017 |
|
|
2024
Q3 | – | Sell |
-35,000
| Closed | -$3.23M | – | 8229 |
|
|
2024
Q2 | $3.23M | Sell |
35,000
-89,000
| -72% | -$7.88M | ﹤0.01% | 4021 |
|
|
2024
Q1 | $11.8M | Buy |
124,000
+104,000
| +520% | +$8.74M | ﹤0.01% | 2824 |
|
|
2023
Q4 | $1.52M | Buy |
20,000
+10,000
| +100% | +$696K | ﹤0.01% | 4637 |
|
|
2023
Q3 | $693K | Sell |
10,000
-240,000
| -96% | -$19.3M | ﹤0.01% | 5079 |
|
|
2023
Q2 | $23.6M | Buy |
+250,000
| New | +$21.7M | ﹤0.01% | 1870 |
|
|
2022
Q3 | – | Sell |
-38,400
| Closed | -$3.65M | – | 7941 |
|
|
2022
Q2 | $3.65M | Buy |
+38,400
| New | +$3.98M | ﹤0.01% | 3734 |
|
|
2022
Q1 | – | Sell |
-13,500
| Closed | -$1.75M | – | 8404 |
|
|
2021
Q4 | $1.75M | Sell |
13,500
-1,700
| -11% | -$198K | ﹤0.01% | 4696 |
|
|
2021
Q3 | $1.72M | Sell |
15,200
-98,300
| -87% | -$11.2M | ﹤0.01% | 4586 |
|
|
2021
Q2 | $11.8M | Buy |
113,500
+58,200
| +105% | +$5.49M | ﹤0.01% | 2669 |
|
|
2021
Q1 | $4.63M | Buy |
55,300
+41,800
| +310% | +$3.53M | ﹤0.01% | 3477 |
|
|
2020
Q4 | $1.23M | Buy |
+13,500
| New | +$1.12M | ﹤0.01% | 4326 |
|
|
2020
Q1 | – | Sell |
-6,600
| Closed | -$513K | – | 6955 |
|
|
2019
Q4 | $513K | Sell |
6,600
-207,000
| -97% | -$16.2M | ﹤0.01% | 4996 |
|
|
2019
Q3 | $15.7M | Buy |
213,600
+207,000
| +3,136% | +$14.5M | ﹤0.01% | 2069 |
|
|
2019
Q2 | $406K | Buy |
+6,600
| New | +$399K | ﹤0.01% | 5202 |
|
|
2018
Q2 | – | Sell |
-1,500
| Closed | -$70K | – | 7143 |
|
|
2018
Q1 | $70K | Sell |
1,500
-65,100
| -98% | -$2.83M | ﹤0.01% | 5903 |
|
|
2017
Q4 | $2.5M | Hold |
66,600
| – | – | ﹤0.01% | 3762 |
|
|
2017
Q3 | $2.43M | Hold |
66,600
| – | – | ﹤0.01% | 3817 |
|
|
2017
Q2 | $2.63M | Sell |
66,600
-45,000
| -40% | -$1.64M | ﹤0.01% | 3646 |
|
|
2017
Q1 | $3.5M | Sell |
111,600
-1,200
| -1% | -$37.6K | ﹤0.01% | 3361 |
|
|
2016
Q4 | $3.52M | Buy |
112,800
+37,800
| +50% | +$1.22M | ﹤0.01% | 3276 |
|
|
2016
Q3 | $3.01M | Sell |
75,000
-88,200
| -54% | -$3.32M | ﹤0.01% | 3293 |
|
|
2016
Q2 | $5.42M | Sell |
163,200
-264,300
| -62% | -$9.04M | ﹤0.01% | 2739 |
|
|
2016
Q1 | $12.6M | Buy |
+427,500
| New | +$11.8M | ﹤0.01% | 1954 |
|
|
2015
Q1 | – | Sell |
-216,000
| Closed | -$4.59M | – | 7191 |
|
|
2014
Q4 | $4.59M | Buy |
216,000
+202,800
| +1,536% | +$4.07M | ﹤0.01% | 2631 |
|
|
2014
Q3 | $225K | Buy |
13,200
+6,000
| +83% | +$94.7K | ﹤0.01% | 5286 |
|
|
2014
Q2 | $103K | Sell |
7,200
-5,400
| -43% | -$73.2K | ﹤0.01% | 6117 |
|
|
2014
Q1 | $156K | Sell |
12,600
-239,400
| -95% | -$2.76M | ﹤0.01% | 5638 |
|
|
2013
Q4 | $2.76M | Buy |
252,000
+6,000
| +2% | +$67.6K | ﹤0.01% | 3011 |
|
|
2013
Q3 | $2.85M | Buy |
246,000
+6,000
| +3% | +$70.2K | ﹤0.01% | 2902 |
|
|
2013
Q2 | $2.69M | Buy |
+240,000
| New | +$2.84M | ﹤0.01% | 2886 |
|
Other funds holding EW
VCM
VPM
Bank of America's EW Position: Q1 2026 in Review
Bank of America increased its Edwards Lifesciences (EW) stake by 132% in Q1 2026, buying an estimated $182M and bringing the position to 3,883,419 shares worth $311M. The position accounts for 0.02% of the portfolio, ranked #553.
Bank of America first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $690M in Q4 2021. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Bank of America held 3,883,419 shares of Edwards Lifesciences worth $311M as of Q1 2026.
- Bank of America bought 2,212,208 Edwards Lifesciences shares in Q1 2026, an estimated $182M.
- Edwards Lifesciences made up 0.02% of Bank of America's portfolio in Q1 2026, its #553 holding.
- Bank of America first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Bank of America's Edwards Lifesciences position peaked at $690M in Q4 2021.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.